Gene shinc-3 and diagnostic and therapeutic uses thereof

Details Gene shinc-3 and diagnostic and therapeutic uses thereof Gene shinc-3 and diagnostic and therapeutic uses thereof

2007-07-17

2007-07-17

Foley, Shanon (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S023100

Reexamination Certificate

active

10411930

ABSTRACT:
The invention provides a SHINC-3 polynucleotide, which can be a nucleic acid encoding all or a portion of a SHINC-3 protein, or a complementary polynucleotide or antisense polynucleotide. In another aspect, the invention provides a SHINC-3 polypeptide, which can be a full-length SHINC-3 protein or a fragment thereof or an analog or homolog thereof. Desirably, the SHINC-3 polypeptide modulates apoptosis. In another aspect, the invention provides an antibody that specifically binds a SHINC-3 polypeptide.In another aspect, the invention provides diagnostic methods. For example, the method affords a method for identifying compounds that modulate apoptosis. In another aspect, the invention provides a method for detecting or evaluating the prognosis of a cancer. In another aspect, the invention provides diagnostic compositions for detection of cancer.In another aspect, the invention provides a method of modulating apoptosis or invention or preventing a cancer, tumor growth and/or metastasis by administration of an agent that modulates the expression and/or activity of SHINC-3.In another aspect, the invention provides formulations of SHINC-3 polynucleotides or proteins. Preferably, such compositions will comprise liposomal formulations.

REFERENCES:
patent: RE30985 (1982-06-01), Cartaya
patent: 4399216 (1983-08-01), Axel et al.
patent: 4551433 (1985-11-01), DeBoer
patent: 4560655 (1985-12-01), Baker
patent: 4657866 (1987-04-01), Kumar
patent: 4745051 (1988-05-01), Smith et al.
patent: 4767704 (1988-08-01), Cleveland et al.
patent: 4777127 (1988-10-01), Suni et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4889806 (1989-12-01), Olson et al.
patent: 4927762 (1990-05-01), Darfler
patent: 4929555 (1990-05-01), Cregg et al.
patent: 4959314 (1990-09-01), Mark et al.
patent: 5013830 (1991-05-01), Ohtsuka et al.
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5149655 (1992-09-01), McCabe et al.
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5185440 (1993-02-01), Davis et al.
patent: 5206152 (1993-04-01), Sukhatme
patent: 5217879 (1993-06-01), Huang et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5403711 (1995-04-01), Walder et al.
patent: 5422120 (1995-06-01), Kim
patent: 5491133 (1996-02-01), Walder et al.
patent: 5514758 (1996-05-01), Muller et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5536821 (1996-07-01), Agrawal et al.
patent: 5541306 (1996-07-01), Agrawal et al.
patent: 5550111 (1996-08-01), Suhadolnik et al.
patent: 5563253 (1996-10-01), Agrawal et al.
patent: 5565350 (1996-10-01), Kmiec
patent: 5565552 (1996-10-01), Magda et al.
patent: 5567810 (1996-10-01), Weis et al.
patent: 5571799 (1996-11-01), Tkachuk et al.
patent: 5574142 (1996-11-01), Meyer, Jr. et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5585481 (1996-12-01), Arnold, Jr. et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5587371 (1996-12-01), Sessler et al.
patent: 5597696 (1997-01-01), Linn et al.
patent: 5610018 (1997-03-01), Di Fiore et al.
patent: 5625050 (1997-04-01), Beaton et al.
patent: 5641670 (1997-06-01), Treco et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5700922 (1997-12-01), Cook
patent: 5776745 (1998-07-01), Ketner et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5919773 (1999-07-01), Monia et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5958773 (1999-09-01), Monia et al.
patent: 6333314 (2001-12-01), Kasid et al.
patent: 36776 (1981-09-01), None
patent: 0 127 839 (1984-12-01), None
patent: 0 155 476 (1985-09-01), None
patent: 0 244 234 (1987-11-01), None
patent: 0 345 242 (1989-12-01), None
patent: 0 415 731 (1991-03-01), None
patent: 0 524 968 (1993-02-01), None
patent: 1074617 (2001-02-01), None
patent: 2 200 651 (1988-08-01), None
patent: WO 87/00195 (1987-01-01), None
patent: WO 90/03430 (1990-04-01), None
patent: WO 90/07936 (1990-07-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 91/00357 (1991-01-01), None
patent: WO 91/02805 (1991-03-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/14445 (1991-10-01), None
patent: WO 92/05266 (1992-04-01), None
patent: WO 92/10578 (1992-06-01), None
patent: WO 92/11033 (1992-07-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/04170 (1993-03-01), None
patent: WO 93/06248 (1993-04-01), None
patent: WO 93/09239 (1993-05-01), None
patent: WO 93/10218 (1993-05-01), None
patent: WO 93/11230 (1993-06-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 93/25234 (1993-12-01), None
patent: WO 93/25698 (1993-12-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 94/03622 (1994-02-01), None
patent: WO 94/12649 (1994-06-01), None
patent: WO 94/15645 (1994-07-01), None
patent: WO 94/21792 (1994-09-01), None
patent: WO 94/23697 (1994-10-01), None
patent: WO 94/28938 (1994-12-01), None
patent: WO 95/00655 (1995-01-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/13796 (1995-05-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/27069 (1995-10-01), None
patent: WO 95/30763 (1995-11-01), None
patent: WO 96/30498 (1996-10-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 00/00157 (2000-01-01), None
patent: WO 02/059337 (2002-08-01), None
patent: WO 02/081639 (2002-10-01), None
patent: WO 02/081640 (2002-10-01), None
patent: WO 02/081641 (2002-10-01), None
patent: WO 02/081642 (2002-10-01), None
Riedel et al., “The Mitogenic Response of T Cells to Interleukin-2 Requires Raf-1”,Eur. J. Immunol., 23, 3146-3150 (1993).
Suy et al., “Nitroxides Tempol and Tempo Induce Divergent Signal Transduction Pathways in MDA-MB 231 Breast Cancer Cells”,J. Biol. Chem., 273, 17817-17878 (1998).
Tornkvist et al., “Inhibition of Raf-1 Kinase Expression Abolishes Insulin Stimulation of DNA Synthesis in H4IIE Hepatoma Cells”,J. Biol. Chem., 269, 13919-13921 (1994).
Bruder et al., “Serum-, TPA-, and Ras-induced expression from AP-1/Ets-driven promoters requires Raf-1 kinase,”Genes&Dev., 6, 545-556 (1992).
Bruhn et al., “Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distions to DNA caused by binding of the anticancer agent cisplatin,”Proc. Natl. Acad. Sci. USA, 89, 2307-2311 (1992).
Cozens et al., “DNA sequences of two expressed nuclear genes for human mitochondrial ADP\ATP translocase,”J. Mol. Biol., 206, 261-280 (1989).
Davis, “The many faces of epidermal growth factor repeats,”New Biol., 22, 410-419 (1990).
Dent et al. “Activation of mitogen-activated protein kinase kinase by v-Raf in NIH3T3 cells and in vitro,”Science, 257, 1404-1407 (1992).
Devary et al., “The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases,”Cell, 71, 1081-1091 (1992).
Dinchuk et al., “Aspartyl â-hydroxylase (Asph) and an evolutionarily conserved isoform of asph missing the catalytic domain share exons with junctin,”J. Biol. Chem., 275, 39543-39554 (2000).
Downing et al., “Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorder,”Cell, 85, 597-605 (1996).
Fiermonte et al, “Identification of the human mitochondrial oxodicarboxylate carrier,”J. Biol. Chem., 276, 8225-8230 (2001).
Finco et al., “κB site-dependent induction of gene expression by diverse inducers of nuclear factor κB requires Raf-1,”J. Biol . Chem., 268, 17676-17679 (1993).
Gokhale et al., “AntisenserafOligodexyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: Implication for gene therapy of radioresistant cancer,”Gene Therapy, 4, 1289-1299 (1997).
Green et al., “Mitochondria and Apoptosis,”

Affiliated with

Also associated with

Rating

Gene shinc-3 and diagnostic and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene shinc-3 and diagnostic and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene shinc-3 and diagnostic and therapeutic uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3797204